Amicus Therapeutics (FOLD) Tops Q3 EPS by 3c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
November 4, 2025 7:01 AM ESTQ3 2025 Total Revenue of $169M, up 17% at CER
Positive Q3 2025 GAAP Net Income of $17M
Cash Position of $264M, a $33M Increase in Q3 2025
Conference Call and Webcast Today at 8:30 a.m. ET
PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:... More
